159
305. Pinson M. Periodontal disease and type I diabetes mellitus in children and
adolescents / M. Pinson, W.H. Hoffman, J.J. Garnick [et al] // J. of Clinical
Periodontology. – 1995. – Vol.22. – P.23-28.
306. Porter C. Oral and maxillofacial medicine: the basis of diagnosis and
treatment, 3rd edition // British Dental Journal. – 2013. – Vol.214. – P. 423-426.
307. Poulaki S. Demenzerkrankungen / S. Poulaki, B. Wiegele // BZB
Wissenschaft und Fortbildung. – 2009. – №7-8. – Р.59-63.
308. Raskind M.A. The cognitive benefits of galantamine are sustained for at least
36 months: a long-term extension trial / M.A. Raskind, E.R. Peskind, L. Truyen
[et al.] // Arch Neurol. – 2004, – Vol.61, №2. – P.252-256.
309.
Reich Е. Kariesprophylaxe heute //
BZB Wissenschaft und Fortbildung. –
2010. –№6. – Р.56-60.
310.
Restrepo S.
Older People May Lose Ability to Differentiate Odors,
Researchers Report
// J. American. Dental Association. – 2012. – Vol.143, №2. –
Р.111-112.
311. Rimm E.B. Diet, lifestyle and longevity-the next steps / E.B. Rimm, M.J.
Stamfler // JAMA.
–
2004.
–
Vol.292, №12.
–
P.1490-1492.
312. Rockwood K. Effects of a flexible galantamine dose in Alzheimer’s disease:
a randomized, controlled trial / K. Rockwood, J. Mintzer, L. Truyen [et al.] // J.
Neurol Neurosurg. Psychiatry. – 2001. – Vol.71, №.5. – P.589-595.
313. Salvi G.E. Monocytic TNFa secretion patterns in IDDM patients with
periodontal diseases / G.E. Salvi, J.G.Collins, B. Yalda [et al.] // J. of Clinical
Periodontology. – 1997. – Vol.24. – P.8-16.
314. Salvi G.E. Inflammatory mediator response as a potential risk marker for
periodontal diseases in insulin-dependent diabetes mellitus patients / G.E. Salvi,
J.G. Collins, B. Yalda [et al.] // J. of Clinical Periodontology. – 1997. – Vol.68. –
P.127-135.